Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
BioSenic SA is a biotechnology company specializing in regenerative and immune medicine, developing innovative products for inflammatory diseases, bone disorders, and related medical devices. Formed through the 2022 merger of Medsenic and Bone Therapeutics, it leverages the arsenic trioxide (ATO) platform to create anti-inflammatory and anti-autoimmune formulations, including oral ATO (OATO), targeting conditions such as graft-versus-host disease (GvHD), systemic lupus erythematosus (SLE), and systemic sclerosis (SSc). The company also advances orthopedics and regenerative therapies, with historical focus on cell therapies for bone regeneration, osteonecrosis, fractures, and osteoarthritis, though it has shifted away from direct development of certain assets like JTA-004 and ALLOB. Currently, BioSenic co-develops 4P004v with 4Moving Biotech, a veterinary GLP-1 analog for post-surgical ligament repair in dogs, addressing a key unmet need in veterinary orthopedics. Headquartered in Belgium with a small team of two employees, BioSenic emphasizes clinical assets for high-value indications, collaborative innovation, and accelerated market paths in the pharmaceuticals sector.
€0.00
+€0.00 (+0.00%)
Price from 2 days ago
ROIC dropped from -12.05% to -20.20%, capital efficiency is deteriorating. Negative free cash flow of -€3M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€0.00
Net Income (TTM)
-€29M
▼ -851.8% YoY
Op. Margin
—
ROIC
-20.20%
▼ -8.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€3M
▼ -81.2% YoY
Op. Cash Flow (TTM)
-€3M
▼ -81.4% YoY
Net Debt
€28M
Cash & Equiv.
€117K
Continue Research
BioSenic SA (BIOS.XBRU)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, BioSenic SA scores 0/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
BioSenic SA scores 0 out of 100 on Intrinsiqq's quality score, passing 0 of 4 checks, which makes it a lower-quality business on these measures. Recent fundamentals include a -20.2% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh BIOS.XBRU's valuation and scores 0/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.